

Nanon Technologies is pleased to welcome Dr. Ronald Knox to the team

Livingston, N.Y. USA, 19. November 2018: Nanon is pleased to announce the recent hire of Dr. Ronald Knox as Account Executive, who brings 18+ years of experience in drug discovery, target validation and translational research in neuroscience, cardiovascular and immunotherapies.

Within his new role, he will help drive business development and support for the CardioExcyte 96 and Syncropatch 384/768PE systems. Dr. Knox will leverage his Biopharma and academic networks



to better understand the evolving landscape of CV ion channel safety pharmacology to help strengthen Nanon's strategic support and commitment to the implementation of technology platforms that are comprehensively aligned with the global "Comprehensive In Vitro Proarrhythmia Assay" (CiPA) initiative.

Dr. Knox helped establish patch clamp electrophysiology as a core competency in the Bristol-Myers Squibb centralized Lead Discovery & Optimization Department to support multiple therapeutic area ion channel programs (Neuroscience, CV, Immunology and Metabolic Diseases), including the implementation of several automated technology platforms to drive ion channel hit identification and SAR processes. He earned his bachelor's degree in pharmacology from the University of Glasgow, UK and received his PhD in Neuropharmacology from University College London, UK.



"I am delighted to join Nanon Technologies, globally recognized for their engineering and scientific expertise in the delivery and support of premier performance automated electrophysiology solutions for biopharma drug discovery and academic research applications. The unique opportunity of Nanon's premier quality technology platforms to play a substantial role in the delivery of near future critical CiPA data and next generation ion channel screening was a key driver in my decision to join the company" noted Dr. Knox



Dr. Sonja Stölzle-Feix, Director Scientific Affairs of Nanon states: "I'm very happy to have Ron on board to continue to increase customer confidence in Nanon's products for CiPA experiments including using CiPA approved protocols for, e.g. hERG kinetics and other

cardiac ion channels on our automated patch clamp platforms. For HTS ion channel screening, generating data in a format that can be used to create in silico modelling data will be a key factor to many customers doing cardiac safety experiments in the near future. In addition, Nanon is working together with the FDA to write the myocyte best practices protocols and Ron has an excellent background to support the ongoing CiPA projects here at Nanon."

About Nanon Technologies:

Nanon Technologies is a leading provider of instrumentation for ion channel drug discovery and screening. Founded in 2002, Nanon has grown over the last 16 years to a company with over 100 employees worldwide. With headquarters in Munich, Germany, Nanon has subsidiaries in the USA, Denmark, Japan and China, as well as distribution partners in seven other countries.

Nanion's team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit family), and for parallel membrane transporter protein recordings (SURF²R).

Contact Details:

Dr. Ronald Knox, Account Executive Nanion USA,
Phone: +1 (862) 333-6048
E-mail: Ronald.Knox@naniontech.com

Dr. Sonja Stölzle-Feix, Director, Scientific Affairs Nanion
Technologies Munich Germany,
Phone: +49 89 2190 95 – 073
E-mail: sonja.stoelzle-feix@nanion.de

Dr. Gesa Rascher-Eggstein, Marketing Manager Nanion
Munich Germany
Phone: +49 89 2190 95 - 073
Email: gesa.rascher-eggstein@nanion.de